Stroke and transient ischaemic attack (TIA) remain controversial indications for echocardiography. In some centres they represent 40-50% of the total requests for transoesophageal studies, while many stroke units never request echocardiography as a matter of routine. We need to examine the reasons for these wide differences in practice.
In a patient with mitral stenosis, echocardiography may reveal a ball thrombus for which the management becomes urgent surgery rather than simply anticoagulation.
Atrial fibrillation is a marker for stroke rather than necessarily the direct cause. It is associated with other conditions such as hypertension or heart failure, which themselves carry an independent risk of stroke. For this reason atrial fibrillation is found in 1 1% of patients suffering cerebral haemorrhage as well as 25-35% of those with cerebral thrombosis. These figures are lower than the incidence of 60% in patients with embolism,4516 but they still underline that brain imaging to exclude haemorrhage should always be performed in patients in atrial fibrillation before starting anticoagulation.
How important is transoesophageal echocardiography? In contrast to transthoracic echocardiography, the transoesophageal approach frequently shows abnormalities even in the absence of clinical signs (table 4) . These include patent foramen ovale, atrial septal aneurysm, left atrial spontaneous contrast, left atrial thrombus, and aortic atheroma. However, the importance of many of these findings is difficult to evaluate because of a lack of standardisation of definitions and a relative lack of control comparisons.
PATENT FORAMEN OVALE Some authors consider a patent foramen ovale present if five or more microcavitations are seen within three cycles,'7 some if only three are seen,13 and some only two18 or even one.14l9
There is some evidence that the number of microcavitations is approximately related to the anatomical size of the patent foramen ovale."9 A reasonable arbitrary grading is between one and five (small), five to 20 (moderate), and more than 20 (large). Most authors make between three and six injections and most use a Valsalva manoeuvre that increases the yield of patent foramen ovale by at least (table 5) . Cryptogenic strokes are cerebral infarcts with no obvious cause on ultrasound scanning of the carotid system or haematological analysis, and with no atrial fibrillation or other clinical evidence of heart disease. A small number of studies have shown a higher incidence of patent foramen ovale, up to 56%, in cryptogenic than in total stroke.'719 However, other studies have failed to show an increased incidence.'6 Furthermore, a similar figure (23%) has been found in most control patients.41822
This similar incidence in patients with stroke and in control subjects has been interpreted to mean that patent foramen ovale is not a valid cause of stroke.'8 The mechanism proposed certainly sounds intuitively unlikely. A venous embolism must be passing the region of the fossa ovalis at the precise time that right atrial pressure exceeds left atrial pressure sufficient for the foramen to open. The foramen must also be large enough to accommodate an embolic particle; the passage of a few microbubbles that are usually only 15-20,m in diameter23 24 may not prove this. It is also thought that it is uncommon to find a source for venous emboli in patients with stroke and patent foramen ovale.25 However, this is an area of controversy because of the practical difficulty in venous imaging soon enough after admission because of stroke to detect primary rather than secondary thrombosis. One study found a deep vein thrombosis in 49 of 264 (19%) patients after stroke compared with historically expected figures of 4-13%. 26 However, in this study venography was performed up to 90 days after the stroke and there were no control studies. Hanna et al23 found deep vein thrombosis in five of 16 (31 %) patients with patent foramen ovale alone (cryptogenic stroke), compared with only one of 23 patients (4%) with patent foramen ovale and an additional cause for stroke, and only one of 35 patients (3%) with a patent foramen ovale but no stroke. There is also anecdotal evidence that even large thrombi may catch in a patent foramen27 particularly in patients with raised right sided pressures as a result of pulmonary emboli.'8 Thus, overall there is sufficient evidence to support the concept of patent foramen ovale as a cause of stroke, although as in other fields the echocardiographic abnormality cannot be interpreted outside the clinical context. If a patent foramen ovale is found in a patient with cryptogenic stroke, it is more likely to be significant than in a patient with another potential cause for stroke. Some abnormalities may not genuinely be related to stroke. For example, although mitral prolapse has been reported in up to 40% of patients with ischaemic stroke,34 in most studies it is far less common and in some there were no cases at all.' In the large SPAF study'5 the incidence was 5%, the same as in the control group. Furthermore the incidence of stroke in patients with mitral prolapse is low and can be accounted for by other associated factors such as atrial fibrillation.3536
Mitral annular calcification may be related to stroke although the cause is not clear. In the Boston trial37 of warfarin in non-rheumatic atrial fibrillation, mitral annular calcification was present in 67% of patients with stroke compared with 29% without. A link between mitral annular calcification and aortic atheroma has been postulated although never tested, and at present we believe that there is insufficient evidence to assume that mitral annular calcification is an independent risk factor for stroke, nor is it clear how finding mitral annular calcification should alter management. Does transoesophageal echocardiography affect management? Many studies overemphasise the role of echocardiography in stroke by reporting even mild degrees of valve thickening or mitral prolapse leading to a rate of abnormality as high as 83%.4 Many of these patients have other causes of stroke such as atrial fibrillation or carotid atheroma, and a comprehensive assessment of the patient must be made rather than relying on the echocardiogram alone. Even then, about 30% of patients will have a potentially important abnormality on transoesophageal echocardiography.
Do these findings change management? In most cases where left atrial spontaneous contrast or thrombus are found the patient is in atrial fibrillation so will already have been anticoagulated with warfarin (in the absence of contraindications). If the risk of haemorrhage has been judged too high to start warfarin, the Table 1I Recommendations for performing transoesophageal echocardiography 1 . Look at left atrium and left atrial appendage for thrombus and spontaneous contrast 2. Check the atrial septum for myxoma, aneurysm (excursion > 15 mm), and atrial septal defect using imaging and colour. If there is an aneurysm look for thrombus and spontaneous contrast 3. Perform a contrast study. Use 10 ml dextrose saline or saline with 1 ml air and 1 ml of the patient's blood shot between two syringes using a three way tap and injected at speed on three occasions using different views of the atrial septal aneurysm. Grading of patent foramen ovale small 
